newsfilter
← Latest News
GlobeNewswire·

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral candidate being developed for norovirus treatment and preventionNo approved treatments or vaccines